POST. MIKROBIOL., 2004, 43, 1, 107-127 http://www.pm.microbiology.pl

MOLEKULARNE MECHANIZMY ODPORNOŚCI NA GRUŹLICĘ

Wiesława Rudnicka

 Wprowadzenie. 2. Pierwotne zakażenie *Mycobacterium tuberculosis*. 3. Los mikobakterii w makrofagach. 4. Aktywacja komórek dendrytycznych i makrofagów przez mikobakterie.
Rola cytokin w przebiegu zakażeń wywoływanych przez mikobakterie. 6. Szczepionki rekombinantowe BCG. 7. Uwagi końcowe

Molecular mechanisms of resistance to tuberculosis

Tuberculosis is a major infectious disease with up to a third of the world's Abstract: population infected, 8-10 million people developing the active disease and about 3 million dying of tuberculosis each year. One key to the pathogenic potential of tubercule bacilli lies in their capacity to resist destruction by macrophages. The development of genomics, proteomics and transcriptomics have shed light on the exploitation of macrophages by mycobacteria. The initial interaction between mycobacterial surface components and numerous macrophage receptors is critical in determining the fate of the bacteria in a phagocyte. The inhibition of fagosom-lysosome fusion by pathogenic mycobacteria promote their intracellular persistence and growth. Dendritic cells which exhibit the unique ability to activate naive T lymphocytes are critical for triggering innate and acquired antimycobacterial immunity. A large body of data show the regulatory role of numerous cytokines and chemokines in the outcome of mycobacterial infection. The recognizing of the cytokines which up-regulate and down-regulate protective immunity to tuberule bacilli could lead the way to innovative therapeutic approaches. The effectiveness of the currently used tuberculosis vaccine, Bacillus Calmette-Guerin (BCG) has been highly variable. Recombinant BCG bacilli with an over production of some mycobacterial antigens or cytokines have been shown to be more effective in generating anti-mycobacterial immunity in mice and guinea pigs than the parental BCG bacilli.

1. Introduction. 2. The primary infection with *Mycobacterium tuberculosis*. 3. The fate of mycobacteria in macrophages. 4. The activation of dendritic cells and macrophages by mycobacteria. 5. The role of cytokines in the outcome of mycobacterial infections. 6. Recombinant BCG vaccine. 7. Conclusions

Zakład Immunologii Komórkowej, Katedra Immunologii i Biologii Infekcyjnej Instytut Mikrobiologii i Immunologii, Uniwersytet Łódzki ul. Banacha 12/16, 90-237 Łódź, e-mail: rudw@uni.lodz.pl